Acute renal failure associated with Pemetrexed (Alimta®);Fracaso renal agudo asociado a Pemetrexed (Alimta®)

Nefrologia

Volumn 29, Issue 6, 2009, Pages 610-611

  Porta, José María Peña ^a   de Vera Floristán, C Vicente ^b   Inglán, P Bueso ^a   Jericó, J Florián ^a  

^a HOSPITAL DE BARBASTRO   (Spain)

^b HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; PEMETREXED;

ACUTE KIDNEY FAILURE; CASE REPORT; CHEMICALLY INDUCED DISORDER; HUMAN; LETTER; MALE; MIDDLE AGED;

ANTINEOPLASTIC AGENTS; GLUTAMATES; GUANINE; HUMANS; KIDNEY FAILURE, ACUTE; MALE; MIDDLE AGED;

EID: 75349084030     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.2009.29.6.5492.en.full     Document Type: Letter

References (6)

1. Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, et al. Phase I and pharmacokinetic study of Pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 2006;24:552-62.
2. Hazarika M, White RM, Johnson JR, Pazdur R. FDA drug approval summaries: Pemetrexed (Alimta®). Oncologist 2004;9:482-8.
3. Brandes JC, Grossman SA, Ahmad H. Alteration of Pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literature. Cancer Invest 2006; 24:283-7.
4. Vootukuru V, Ping Y, Nally JV. Pemetrexedinduced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer. Med Oncol 2006;23:419-22.
5. Castro M. Thymidine rescue: an antidote for pemetexed-related toxicity in the setting of acute renal failure. J Clin Oncol 2003;21:4066.
6. Arman A, White RM. Cytotoxic anticancer agents and renal impairement study: the challenge remains. J Clin Oncol 2006;24:533-6.